ABOUT SOLENO
Soleno is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
OUR SCIENCE
The Company’s lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program.
OUR PROGRAMS
We are focused on developing effective therapeutic options to address the most burdensome aspects of Prader-Willi syndrome (PWS).
INVESTORS
Soleno is committed to maximizing shareholder value by developing and commercializing safe and effective therapeutic products that improve the lives of patients living with complex, life-threatening rare diseases with unmet medical needs.
Developing novel therapeutics for the treatment of rare diseases